Sentences with phrase «in cholangiocarcinoma»
A Role for Focal Adhesion Kinase Signaling in Tumor Necrosis Factor - α — Dependent Matrix Metalloproteinase - 9 Production in a Cholangiocarcinoma Cell Line, CCKS1
http://cancerres.aacrjournals.org/
Upregulation of retinoic acid receptor - ß reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Not exact matches
«In 3 out of the 6 patients we analyzed, we found compelling, treatable and unexpected genetic alterations that would never have been found by normal testing methods for cholangiocarcinoma,» says Mitesh Borad, M.D., a Mayo Clinic oncologist and lead author of the paper.
Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature.
The parasites can cause cholangiocarcinoma, a highly lethal bile duct cancer that is rare in the Western world but nearly 50 times more common (85 cases per 10,000 people) in Northeast Thailand, a hotspot of liver fluke infestation.
A Phase 3, Multicenter, Randomized, Double - Blind, Placebo - Controlled Study of AG - 120 in Previously - Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma
A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
A board - certified general surgeon and surgical oncologist, Kevin Roggin, MD, specializes in the surgical treatment of complex upper gastrointestinal tract and hepato - pancreato - biliary (HPB) cancers (stomach, pancreas, liver, gallbladder, gastrointestinal stromal tumors (GIST), sarcomas, extrahepatic bile duct cholangiocarcinoma).
An Open - Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B - 6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Agents we are investigating include anti-angiogenic therapeutics (avastin), EGFR inhibitors (cetuximab), BRAF inhibitors and mTOR inhibitors, in colorectal cancer, gastric cancer and cholangiocarcinoma.
Dr. Azad's clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma / pancreaticobiliary tract cancer.
Cholangiomas and cholangiocarcinomas are rare in both dogs and cats but less rare in cats and most such cases occur in cats over ten years of age.
Cholangiocarcinoma is a cancerous growth in one of the ducts that carries bile from the liver to the small intestine.